Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
FRNM
Freenome, Inc.
Freenome, Inc. (FRNM) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (C).
Quantitative Factor Evaluation • Updated
Overall Rating
2.8
/ 5.0
C+
Value
C+
Factor Score
2.8
/ 5.0
Growth
B
Factor Score
3.3
/ 5.0
Profitability
C
Factor Score
2.2
/ 5.0
Momentum
B
Factor Score
3.3
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-4.8
EV / EBITDA
-13.3
Rev Growth YoY
106.5%
Gross Margin
0.0%
Price Return 3M
-0.4%
Price Return 12M
8.0%
Catalyst Signal
0.00
Market Cap
$1.2B
TTM Revenue
$35.4M
Price / Sales
35.1
ROE
N/A
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.8) | B (3.3) | C (2.2) | B (3.3) | C+ (2.6) | C+ (2.8) |
| 2026-11-05 | C+ (2.8) | B (3.3) | C (2.2) | A- (4.0) | C+ (2.7) | B- (3.0) |
| 2026-10-29 | C+ (2.8) | B (3.3) | C (2.4) | A- (4.1) | C+ (2.7) | B- (3.0) |
| 2026-10-22 | C+ (2.8) | B (3.3) | C (2.3) | B+ (3.8) | C+ (2.6) | B- (3.0) |
| 2026-10-15 | C+ (2.8) | B (3.3) | C (2.3) | B (3.4) | C+ (2.6) | B- (2.9) |
Page
1
of
3